On 20 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2018. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the...

Sobi™ will present data at the European Association of Haemophilia and Allied Disorders (EAHAD) conference in Prague, Czech Republic, 6-8 February 2019, showing evidence on the safety, efficacy and long-term benefits of its extended half-life products for the treatment...

New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

As per 31 January 2019, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi™) amounts to 297,515,209 shares. All shares are common shares. The total number of votes is 297,515,209....

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that Ravicti®, a therapy option for the treatment of patients with urea cycle disorders (UCDs), has received approval from the European Commission on 18 December 2018 for the paediatric indication (birth to two months...